EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study

Yingxia He, Jie Wang, Fang Yao, Pan Lu, Yafang Xie, Xiuwen Li, Qiangwei Liu, Yang Liu, Dan Cao, Jun Liang, Dan Tian, Guan Liu

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00470-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drugs in R&D, 2024. Verfasst von Yingxia He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Delayed-Action Preparations, Therapeutic Equivalency, Venlafaxine Hydrochloride. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Venlafaxine hydrochloride extended-release (ER) capsules are commonly used to treat depression and anxiety disorders. Evaluation of the bioequivalence of generic formulations with reference products is essential to ensure therapeutic equivalence. The objective of this study was to evaluate the bioequivalence, safety, and tolerability of Chinese-manufactured venlafaxine hydrochloride extended-release capsules compared with USA-manufactured EFFEXOR® XR in healthy Chinese volunteers under fed conditions. METHODS: A randomized, open-label, single-dose, crossover study was conducted. Subjects were randomly assigned to receive the test formulation (one 150-mg ER capsule manufactured in China) or the reference formulation (one 150-mg ER capsule manufactured in the USA). The bioequivalence of the two drugs was assessed using the area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) and the maximum observed concentration (Cmax). RESULTS: A total of 28 subjects were enrolled and randomly assigned to receive a single dose of either the test or reference capsule. All the subjects completed the study and were included in the pharmacokinetic (PK) and safety analyses. The mean AUC0-t and Cmax of venlafaxine and its active metabolite O-desmethylvenlafaxine were comparable between the test and reference products with both parameters close to 100% and the corresponding 90% confidence intervals within the specified 80-125% bioequivalence boundary. Safety was also assessed between the two products and all adverse events (AEs) in this study were mild in severity. CONCLUSIONS: Both the test and reference venlafaxine hydrochloride ER capsules were bioequivalent and showed a similar safety and tolerability profile in the population studied. CLINICAL TRIALS REGISTRATION: This study was registered at the Drug Clinical Trial Registration and Information Publicity Platform ( http://www.chinadrugtrials.org.cn/index.html ) with registration number CTR20211243, date: June 1, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Delayed-Action PreparationsTherapeutic EquivalencyVenlafaxine HydrochlorideAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCapsulesChinaCross-Over StudiesDrugs, GenericEast Asian PeopleHealthy Volunteers

Substanzen

CapsulesDelayed-Action PreparationsDrugs, GenericVenlafaxine Hydrochloride

Autor:innen und Institutionen

  • Phase I Clinical Research Center, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, People's Republic of China.
  • Clinical Research Ward, The Central Hospital of WuhanTongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Office of Clinical Research Institutions, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, People's Republic of China. 719385320@qq.com.
  • Office of Tuberculosis Prevention and Control, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, People's Republic of China. liuguantbdoctor@hotmail.com.

Zitieren

APA

He, Y., Wang, J., Yao, F., Lu, P., Xie, Y., Li, X., Liu, Q., Liu, Y., Cao, D., Liang, J., Tian, D., & Liu, G. (2024). Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study. Drugs in R&D. https://doi.org/10.1007/s40268-024-00470-w

Vancouver

He Y, Wang J, Yao F, Lu P, Xie Y, Li X, et al. Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study. Drugs in R&D. 2024. doi:10.1007/s40268-024-00470-w

BibTeX
@article{He2024,
  author = {He, Yingxia and Wang, Jie and Yao, Fang and Lu, Pan and Xie, Yafang and Li, Xiuwen and Liu, Qiangwei and Liu, Yang and Cao, Dan and Liang, Jun and Tian, Dan and Liu, Guan},
  title = {Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00470-w}
}
Kostenlos starten →